ROBERT M. JONES,JUERG LEHMANN,WEICHAO CHEN,JEFFREY EDWARDS,GLEN MARQUEZ,MICHAEL E. MORGAN,ABU J.M. SADEQUE,SUN HEE KIM
申请号：
GT201300075
公开号：
GT201300075A
申请日:
2013.03.18
申请国别(地区):
GT
年份:
2014
代理人:
摘要：
THIS INVENTION REFERS TO THE GPR119 RECEPTOR AGONISTS: 3-FLUORO-4- (5-FLUORO-6- (4- (3- (2-FLUOROPROPAN-2-YL) -1,2,4-OXADIAZOL-5 -YL) PIPERIDIN-1-YL) PYRIMIDIN-4-YLAMINO) -N, N-DIMETHYLBENZAMIDE-FLUORO-4- (5-FLUORO-6- (4- (3- (2-FLUORO-PROPAN-2-YL) -1,2,4-OXADIAZOL-5-YL) PIPERIDIN-1-YL) PYRIMIDIN-4-YLAMINO) -N-METHYLBENZAMIDE AND 3-FLUORO-4- (5-FLUORO-6- (4- (3- ( 2-FLUOROPROPAN-2-YL) -1,2,4-OXADIAZOL-5-YL) PIPERIDIN-1-YL) PYRIMIDIN-4-YLAMINO) BENZAMIDE, AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, AND HYDRAPHS OF THE SAME, WHICH ARE USEFUL AS A SINGLE PHARMACEUTICAL AGENT OR IN COMBINATION WITH ONE OR MORE ADDITIONAL PHARMACEUTICAL AGENTS, SUCH AS, AN DPP-IV INHIBITOR, A BIGUANIDA,An alpha glucose inhibitor, a sterol insulin, a flutamide, an SGLT2 inhibitor, a megletin, a sulfur amide, or an anti diabetic peptide analysis, A disorder related to gpr119, a condition related to the increase of foreign body secretion, a condition improved by the increase of blood level, a condition characterized by low quality, a nerve disorder, a disorder related to metabolism, Type 2 diabetes, obesity and related complications.LA PRESENTE INVENCIÓN SE REFIERE A LOS AGONISTAS DEL RECEPTOR GPR119: 3-FLUORO-4-(5-FLUORO-6-(4-(3-(2-FLUOROPROPAN-2-YL)-1,2,4-OXADIAZOL-5-YL)PIPERIDIN-1-YL)PYRIMIDIN-4-YLAMINO)-N,N-DIMETHYLBENZAMIDE-FLUORO-4-(5-FLUORO-6-(4-(3-(2-FLUORO-PROPAN-2-YL)-1,2,4-OXADIAZOL-5-YL)PIPERIDIN-1-YL)PYRIMIDIN-4-YLAMINO)-N-METHYLBENZAMIDE Y 3-FLUORO-4-(5-FLUORO-6-(4-(3-(2-FLUOROPROPAN-2-YL)-1,2,4-OXADIAZOL-5-YL)PIPERIDIN-1-YL)PYRIMIDIN-4-YLAMINO)BENZAMIDE, Y SALES FARMACÉUTICAMENTE ACEPTABLES, SOLVATOS, E HIDRATOS DE LOS MISMOS, QUE SON ÚTILES COMO UN ÚNICO AGENTE FARMACÉUTICO O EN COMBINACIÓN CON UNO O MÁS AGENTES FARMACÉUTICOS ADICIONALES, TALES COMO, UN INHIBIDOR DE LA DPP-IV, UNA BIGUANIDA, UN INHIBIDOR DE LA ALFA-GLUCOSIDASA, UNA INSULINA ANALÓGICA, UNA SULFONILUREA, UN INHIBIDOR DE SGLT2, UNA MEGLITINIDA, UNA TIAZOLIDINDIONA, O UN ANÁLOGO DE PÉPTIDO ANTI-DIABÉTICO,
